Stop valuing a biotech on its platform slide
Every young biotech has the slide. A circle in the middle labelled with the technology, a dozen arrows pointing out to disease areas, and the word platform somewhere in large type. It is a good slide for a first round. It is a poor way to run a company.
Buyers pay for assets
When a larger company licenses, partners or acquires, it is usually paying for something specific: a candidate with data in a disease it cares about, or a capability it can put a price on. The platform matters because it produced that candidate and might produce the next one. On its own it is a promise, and promises are discounted heavily in a term sheet. Large studies of clinical trial success rates show that most candidates entering clinical testing never reach approval, and buyers price that in.
Founders know this, which is why the platform slide so often survives into later decks while the lead program sits on page eleven. That order is backwards.
We spent two years explaining the platform. The deal happened in six weeks once we had one clean data readout.
Focus is not a lack of ambition
Spreading a small team across five indications to prove breadth usually means none of them reaches a decisive experiment. Choosing one program, funding it to a readout that would change a partner's mind, and saying so plainly, is not small thinking. It is the fastest route to the money that pays for the other four.
What I would put on slide two
The lead candidate, the disease, the patients, and the one result that would make it worth licensing, with a date and a budget to reach it. For a drug candidate, that plan runs through the investigational new drug requirements before any human data exist, which is one more reason to cost it honestly. Then the platform, as the reason there will be a second candidate. Investors who only want the platform story will still find it. The ones who write the larger cheques later will notice you led with the part they pay for.
Buyers further down the line think the same way. A hospital value analysis committee asks what a product changes before it asks how clever it is, and practices want to know whether a new therapy will clear prior authorization and get paid without a pile of claim denials. A company that answers those questions early is easier to partner with.
TL;DR If you only remember this
- Partners and acquirers mostly pay for specific assets and data, not platforms.
- A platform is valued for what it has produced and might produce next.
- Funding one program to a decisive readout often beats spreading across many.
- Lead with the asset and its next milestone; let the platform explain the pipeline.
About the writer
Tomás Ferreira
Devices and biotech writerTomás Ferreira covers medical devices and biotech. A former hospital supply chain analyst who later worked on partnering at a small drug developer, Tomás writes about how products get evaluated, bought and funded, from value analysis committees to licensing term sheets.
More from Tomás →